Prognostic Significance of ypN Status After Neoadjuvant Chemoimmunotherapy in NSCLC

Huan Shao's systematic review and meta-analysis evaluates the association between pathological nodal status (ypN) and survival outcomes in patients with resectable non-small cell lung cancer (NSCLC) treated with neoadjuvant chemoimmunotherapy. The analysis includes hazard ratios for overall survival (OS) and disease-free survival (DFS) pooled from two studies, with results published on figshare in May 2026. The dataset is a 269.5 KB document summarizing the review's methods and findings.

Use Cases

• Evaluate the prognostic value of post-treatment nodal status (ypN) based on pooled hazard ratios for survival outcomes.
• Assess heterogeneity and consistency in survival associations across studies based on the reported I² statistics.
• Compare survival outcomes for different nodal-response contrasts described in the meta-analysis.
• Inform clinical trial design for neoadjuvant chemoimmunotherapy based on the identified prognostic significance.
• Support literature reviews on pathological response classification in NSCLC.

Strengths

• Includes pooled hazard ratios with 95% confidence intervals for overall survival (HR 4.75) and disease-free survival (HR 3.54).
• Follows PRISMA 2020 guidelines for systematic review methodology.
• Has a registered protocol identifier (CRD420261353461).

Limitations

• The primary meta-analyses for OS and DFS each include only two retrospective studies.
• Row count and column-level documentation are unknown; data structure must be inferred from the document.
• The findings are based on prespecified but non-identical nodal-response contrasts, requiring cautious interpretation.

Provenance

Source

Huan Shao

Collection Method

Systematic review and meta-analysis of studies from PubMed, Web of Science, Scopus, Embase, and Cochrane Library.

Time Range

Studies searched from inception to February 26, 2026.

Freshness

Last updated 2026-05-22 04:38:02